Previous 10 | Next 10 |
- 96-week findings support losmapimod as a disease-modifying therapy for FSHD - U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 - Industry Symposium on October 12, 2022, at 4:30pm EDT CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -...
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the ...
Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside...
Fulcrum Therapeutics ( NASDAQ: FULC ) priced an offering of ~9.59M common shares at $7.82 apiece to raise ~$75M in gross proceeds. The company granted the underwriters a 30-day option to buy up to an additional ~1.44M. The offering is expected to close on Aug. ...
Fulcrum Therapeutics ( NASDAQ: FULC ) shares dropped 2% in Monday's extended session after the biotech firm launched an underwritten public offering of $75M of shares of its common stock . Fulcrum also intends to grant the underwriters a 30-day option to purchase up to an ...
Fulcrum Therapeutics, Inc. (FULC) Q2 2022 Earnings Conference Call August 11, 2022 08:00 AM ET Company Participants Stephanie Ascher - Stern, Investor Relations Bryan Stuart - President & Chief Executive Officer Judy Dunn - President, Research & Developme...
Fulcrum Therapeutics press release ( NASDAQ: FULC ): Q2 GAAP EPS of -$0.83 misses by $0.17 . Revenue of $1.9M (-56.6% Y/Y) misses by $1.06M . As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0M, as compared to $218.2M as of Decem...
Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports proof-of-concept that FTX-6058 is a novel oral HbF inducer Announced enrollment of first patient in Phase 3 REACH trial of ...
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial re...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...